![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 33, 29455-29459, August 16, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-N-ACETYLGALACTOSAMINYLTRANSFERASE GENE*
,
¶
From the
Department of Transfusion Medicine,
Institute of Laboratory Medicine, Lund University and Blood Centre,
University Hospital, SE-22185 Lund, Sweden and the
§ International Blood Group Reference Laboratory,
BS105ND Bristol, United Kingdom
Received for publication, March 29, 2002, and in revised form, April 29, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The biochemistry and molecular genetics
underlying the related carbohydrate blood group antigens P,
Pk, and LKE in the GLOB collection and P1 in
the P blood group system are complex and not fully understood.
Individuals with the rare but clinically important erythrocyte
phenotypes P1k and P2k
lack the capability to synthesize P antigen identified as globoside, the cellular receptor for Parvo-B19 virus and some P-fimbriated Escherichia coli. As in the ABO system, naturally occurring
antibodies, anti-P of the IgM and IgG class with hemolytic and
cytotoxic capacity, are formed. To define the molecular basis of the
Pk phenotype we analyzed the full coding region of a
candidate gene reported in 1998 as a member of the
3- The Pk blood group phenotype was recognized in 1959 by
Matson et al. (1) because of antibodies in the serum of a
patient whose erythrocytes were shown to lack an antigen related to but not identical with previously discovered P-related antigens (1). Further studies later showed the P antigen to be globotetraosylceramide (Gb4Cer, globoside,
GalNAc With only few exceptions the molecular basis of the major human blood
group antigens have been determined and the genes responsible for
erythroid expression of the various phenotypes cloned and characterized. However, the biochemistry and molecular genetics behind
the carbohydrate-based P1 antigen in the P blood group system
(numerical nomenclature 003001 according to the International Society
of Blood Transfusion, ISBT)2
and the P, Pk, and LKE antigens in the GLOB collection
(ISBT no. 209001, 209002, and 209003) are complex and not yet fully
understood (6).
Fig. 1 shows the biosynthetic route to
these glycosphingolipid antigens by the sequential addition of
monosaccharide residues to ceramide by different glycosyltransferases
(7). The key enzyme for initiation of globo-series glycolipid
synthesis, UDP-galactose:lactosylceramide 4-
-galactosyltransferase family but later shown to possess
UDP-N-acetylgalactosamine:globotriaosylceramide 3-
-N-acetylgalactosaminyltransferase or globoside
synthase activity. Homozygosity for different nonsense mutations
(C202
T and 538insA) resulting in premature stop
codons was found in blood samples from two individuals of the
P2k phenotype. Two individuals with
P1k and P2k phenotypes
were homozygous for missense mutations causing amino acid substitutions
(E266A or G271R) in a highly conserved region of the enzymatically
active carboxyl-terminal domain in the transferase. We conclude that
crucial mutations in the globoside synthase gene cause the
Pk phenotype.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
3Gal
4Gal
4GlcCer),1
the most abundant neutral glycolipid in the erythrocyte membrane (2) as
well as in other mesodermally derived tissues (3, 4). Later it was
found that human fibroblasts with the Pk phenotype were
deficient in
-N-acetylgalactosaminyltransferase activity
(5).
-galactosyltransferase
(Gb3Cer/Pk/CD77 synthase,
4Gal-T), was
independently cloned by three research teams in the year 2000 (8-10).
Mutations in this gene were shown to constitute the molecular basis of
the p phenotype in which all antigens of the P blood group system and
GLOB collection are lacking on the cell surfaces (8, 11). Attempts to
find polymorphisms in the
4Gal-T gene correlating with P1+/P1
status were fruitless, however (8). Therefore, it is still unclear if
another gene codes for P1 synthase (also an
4Gal-T) or if other
mechanisms exist.

View larger version (28K):
[in a new window]
Fig. 1.
Biosynthetic pathway for globoside and
related substances of the P blood group system and GLOB blood group
collection.
Recently, the
UDP-N-acetylgalactosamine:globotriaosylceramide
3-
-N-acetylgalactosaminyltransferase
(Gb4Cer/globoside synthase, EC 2.4.1.79,
3GalNAc-T1)
gene and its product was characterized by Okajima et al.
(12) using an expression cloning approach (12). Surprisingly enough, it
turned out to be identical to a previously cloned gene, initially
included in the 3-
-galactosyltransferase family based on genetic
homology (13). Although it resembled other 3-
-galactosyltransferases
no enzymatic activity could be defined in the original study (13).
Cells of the p phenotype, which lack P1/P/Pk antigens; of the P2k phenotype, which lack P1/P antigens; and of the P1k phenotype, which lack the P antigen are of principal interest because of potent naturally occurring antibodies that are regularly present in plasma. As in the ABO blood group system, antibodies of the IgM and IgG class (anti-PP1Pk, anti-P1P or anti-P) are made against the missing blood group antigens. While the frequency of the p phenotype in general has been estimated at 5.8 per million (14) it is considerably higher in certain populations, especially in Northern Sweden (15). The frequency of the Pk phenotype is not known but it is generally accepted to be even rarer than p. The frequencies are possibly slightly higher in Finland and Japan but not as marked as for p in Northern Sweden (16).
There are several reasons for the scientific and medical attention spent investigating patients with these rare phenotypes (17). P-related antibodies are implicated in hemolytic transfusion reactions if random antigen-positive blood is transfused. The P, P1, and Pk antigens are well developed on fetal erythrocytes but in most cases relatively mild hemolytic disease of the newborn because of the anti-PP1Pk or anti-P has been reported (16). Women of the p and Pk phenotypes suffer a higher frequency of spontaneous abortion than normal, a phenomenon that is most likely due to the IgG anti-P component (18). The placenta expresses high levels of P and Pk antigen (as opposed to the early fetus itself) and has been suggested as the prime target for these antibodies (19). Another anti-P-mediated disease usually seen in children following a viral infection is paroxysmal cold hemoglobinuria in which P-positive erythrocytes are lysed by a transient auto-anti-P (20).
Globoside/P antigen has also been identified as a cellular receptor for parvo-B19 virus (21) that causes erythema infectiosum, also known as fifth disease, in children and sometimes is complicated by severe aplastic anemia. Complete viral replication and subsequent cell lysis are limited to early erythroid precursor cells expressing the globoside receptor (22). Individuals lacking the receptor appear to be naturally resistant to this infection (23). Finally, it has also been shown that some P-fimbriated E. coli express globoside-binding molecules (PapF and PapG) at the tips of their pili (24), a finding with possible implications for their uropathogenicity.
Because of the relationship to many human pathogens and diseases the
interest in glycolipid-based blood group antigens remains high. In this
study we tested the hypothesis that the reported
3GalNAc-T1/globoside synthase (12) is indeed the enzyme responsible for synthesis of P blood group antigen. By analyzing the coding DNA
sequence of the corresponding gene we show here for the first time that
mutations capable of abolishing enzyme function are present in
individuals with the Pk phenotype.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Blood Samples-- Four blood samples of the Pk phenotype (one P1k and three P2k) were obtained from the liquid nitrogen in-house collection of test cells at the International Blood Group Reference Laboratory (IBGRL). The phenotype of the cells and presence of anti-P in serum were confirmed by standard serological methods at IBGRL and in two cases also by other reference laboratories. For screening of the detected missense mutations blood samples from apparently healthy random blood donors of mixed European descent were used.
DNA Preparation-- DNA was prepared from EDTA or acid-citrate-dextrose blood at the Blood Centre in Lund by a salting out method modified from Miller et al. (25) and dissolved in H2O at a concentration of 100 ng/µl.
PCR Amplification and DNA Sequencing-- Oligonucleotide primers were synthesized by DNA Technology ApS (Aarhus, Denmark). For each reaction 5 pmol of primers P-(-6)-F and P-1015-R or P-123-F and P-891-R (Table I) were mixed with 100 ng of genomic DNA, 2 nmol of each dNTP, 2% glycerol, 1% cresol red, and 0.5 units of AmpliTaq Gold (PerkinElmer/Roche Molecular Biochemicals) in the buffer supplied. The final reaction volume was 11 µl. Thermocycling was undertaken in a GeneAmp PCR system 2400 (PerkinElmer Cetus). Initial denaturation at 96 °C for 7 min was followed by 35 cycles at 94 °C for 30 s, 64 °C for 30 s, 72 °C for 1 min, and a final extension for 2 min. PCR products were excised from 3% agarose gels (Seakem, FMC Bioproducts, Rockland, ME) stained with ethidium bromide (0.56 mg/liter gel, Sigma Chemicals) and purified using the QiaQuick gel extraction kit (Qiagen GmbH, Hilden, Germany). The Big Dye Terminator Cycle sequencing kit (Applied Biosystems Group) and an ABI PRISM 310 Genetic Analyser (Applied Biosystems Group) were used for direct DNA sequencing according to the manufacturer's instructions. Besides the PCR primers, internal primers (Table I) were used as sequencing primers. To avoid artifacts, sequencing was performed on both strands using independently obtained PCR fragments. Sequence analysis was performed with SeqEd software 1.03 (Applied Biosystems Group).
Sequence-specific Primer PCR (PCR-SSP)--
PCR with
allele-specific primers designed to detect the two missense mutations
found in the study was performed. For A797
C detection
2.5 pmol of primer P-797C-null-F and P-1015-R were used together with
0.5 pmol of internal control primers JK-F3L and JK-R3L, modified from
Ref. 26, with PCR conditions as above. For G811
A
detection 7.5 pmol of primer P-811A-null-F and P-1015-R were used instead.
For confirmation of homozygosity consensus primers P-797A-F and
P-811G-F substituted P-797C-null-F and P-811A-null-F at 5 and 10 pmol
per reaction, respectively. The annealing temperature for the
latter reaction was increased to 65 °C for optimal specificity.
| |
RESULTS |
|---|
|
|
|---|
PCR Amplification and DNA Sequencing--
Using the
oligonucleotide primers shown in Table I
the entire coding region of the
3GalNAc-T1 was amplified in one
fragment in samples from donors with the phenotype
P1k (n = 1, English),
P2k (n = 3, Arabian, French,
Finnish), or common GLOB collection/P blood group phenotypes
(n = 2, Swedish). Sequence analysis of the amplified
gene fragments was performed and compared with sequences deposited in
GenBankTM: AB050855 (12) and Y15062 (13). The Swedish
random donors had
3GalNAc-T1 gene sequences identical to the
consensus GenBankTM entries. However, in two of the
P2k samples homozygosity for two distinct
nonsense mutations resulting in premature stop codons were detected.
The Finnish sample was homozygous for C202
T resulting
in an immediate stop codon following residue 67. The Arabian sample was
homozygous for a single adenosine insertion at nucleotide (nt) 537-538
(AG
AAG), here designated 538insA. This insertion causes a
frameshift from amino acid 180 and a premature stop at codon 182 (consensus-Arg180-His181-Stop). The remaining
two samples were homozygous for two different missense mutations. In
the English P1k sample glycine at residue 271 is substituted for arginine because of G811
A whereas
glutamic acid is changed to alanine at residue 266 because of an
A797
C substitution in the French
P2k sample. DNA sequencing chromatograms
visualizing the detected sequences from wild-type and Pk
donors are found in Fig. 2. A schematic
representation of the open reading frames in the consensus and variant
alleles of the
3GalNAc-T1 gene is shown in Fig.
3.
|
|
|
A comparison of glycosyltransferase genes with significant homology
revealed that both of the missense mutations found involve charged
versus non-charged residues in a highly conserved region of
the carboxyl-terminal globular domain of the transferase (Fig. 4). No other deviations from the
3GalNAc-T1 consensus sequence were encountered in any of the
analyzed samples. No mRNA studies could be undertaken due to lack
of fresh samples.
|
Confirmation of Homozygosity--
Because no other
polymorphisms were detected in the
3GalNAc-T1 gene we ensured that
both alleles were amplified for sequence analysis by using two
independent PCR primer pairs, P-(-6)-F and P-1015-R or P-123-F and
P-891-R. In two of the samples the presence of missense mutations and
absence of consensus sequence were confirmed with genomic DNA and
sequence-specific primers. Representative electrophoretograms are shown
in Fig. 5.
|
Screening for Missense Mutations by Sequence-specific Primer PCR
(PCR-SSP)--
DNA samples of 220 mixed European blood donors were
screened for the two missense mutations found during the study to
exclude that they constitute common polymorphisms in the gene. Neither mutation was detected in any of the 440 alleles analyzed.
Representative results outlining the screening procedure are shown in
Fig. 5.
| |
DISCUSSION |
|---|
|
|
|---|
The data presented in this report show that mutations in the
recently cloned
3GalNAc-T1 gene are associated with the clinically important Pk phenotype in which synthesis of the
globoside/P antigen cannot take place. The four samples analyzed were
homozygous for rare alleles, which is not unexpected considering the
low frequency of this phenotype in all populations. This is most
probably due to consanguineous marriages as previously shown in at
least 7 of 33 studied propositi of the Pk phenotype (16).
As is often the case with rare phenotypes when propositi from different
ethnic groups and/or geographic areas are studied the molecular
background for the samples in this study was quite heterogeneous.
Similar data have been obtained for almost all rare blood group
phenotypes with sporadic cases in most populations. Some of these
variant phenotypes have a higher frequency in geographically isolated
populations. A slightly increased frequency of the Pk
phenotype has been noted in Japanese and Finns (16). It is therefore
possible that the allele with C202
T encountered in the
Finnish sample is a founder gene responsible for the Pk
phenotype also in other Finnish cases similar to the situation with the
rare Jk3 negative blood group phenotype in Finns (27).
In two of the investigated samples nonsense mutations at nt 202 or 538 truncate the protein to 20 and 55% of its native length, respectively,
thereby making any retention of enzymic activity impossible because the
enzymatically active domain is in the carboxyl-terminal portion. This
agrees well with other blood group-related glycosyltransferases that
lose activity if severely truncated. For example, the common O allele (O1) in the ABO blood group
system has a single guanosine deletion at nt 261 causing a reading
frameshift that truncates any translated product at residue 117 (28)
leaving no resemblance to A or B transferase after residue 86 (thus
25% of the amino acid sequence remains intact). Other examples are
inactive forms of the FUT2 gene product, the
2-
-fucosyltransferase of the H blood group system, which are
truncated at 55 and 61% of the full reading frame (29).
The other two Pk samples had missense mutations changing
amino acids in the functionally active globular domain in the
carboxyl-terminal portion of the transferase (30). By comparing the
amino acid sequence of homologous genes (Fig. 4) it was shown that the
mutated residues are either invariant or highly conserved among the
sequences compared, suggesting their importance for the function of
3GalNAc-T. Furthermore, they are located in an evolutionarily
conserved cluster of amino acids found in glycosyltransferases
belonging to different functional families (
3Gal-T,
3GalNAc-T,
and
3GlcNAc-T) in humans and also in a Drosophila
homologue, suggestive of importance for this region across species
boundaries and enzyme specificities. Although not expressed and
experimentally proven non-functional by enzyme analysis the data
presented make it highly probable that both the E266A change from a
large negatively charged to a small hydrophobic residue and the G271R
change from a small non-charged to a large positively charged residue
causes enough disturbance in this well conserved region to render the
protein inactive. Again, analogy can be taken from the ABO system where the full-length O2 protein is rendered non-functional by a
G268R change (31, 32) at a conserved residue proposed to be exposed in
the substrate-binding pocket of the 3-
-galactosyltransferase family
(33).
Furthermore, it has been shown unambiguously (14) that the P1 antigen
(putative gene located on chromosome 22) is inherited independently
from the P antigen (globoside synthase gene located on chromosome 3).
Thus, there is no reason to believe that G271R and E266A are specific
for the P1k and P2k
phenotypes, respectively. The frequency of the P1 antigen among Caucasians is ~75%. Any correlation of G811
A
(G271R) to P1+ status was effectively ruled out by PCR-SSP screening of
the 220 samples, none of which were positive for the mutation while the
majority was P1+.
The P antigen may now be extracted from the GLOB collection and
promoted to constitute a blood group system of its own according to the
inclusion criteria set up by the ISBT working party on terminology for
red cell surface antigens. The rule is that a blood group system has to
be defined by a single genetic locus or possibly two (or three) closely
linked loci so that the antigens included in that system are localized
to the same (type of) molecule. Based on the data presented here the P
antigen is now tied to a defined genetic locus different from other
blood group loci and the molecular basis of the null
(P1k and P2k)
phenotypes of the system has been identified.
| |
ACKNOWLEDGEMENT |
|---|
We thank Dr. Alan Chester at the Blood Centre, Lund, Sweden for careful reading of the manuscript and advice concerning carbohydrate and glycosyltransferase nomenclature.
| |
FOOTNOTES |
|---|
* This work was supported in part by the Swedish Research Council, the Medical Faculty at Lund University, the Lund University Hospital Donation Funds, the Claes Högman SAGMAN-stipendium, and Tore Nilson's Fund for Medical Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF494103, AF494104, AF494105, AF494106.
¶ To whom correspondence should be addressed: Blood Centre, University Hospital, SE-221 85, Lund, Sweden. Tel.: 46-46-173210; Fax: 46-46-173226; E-mail: Martin_L.Olsson@transfumed.lu.se.
Published, JBC Papers in Press, May 21, 2002, DOI 10.1074/jbc.M203047200
2 Blood group antigens, phenotypes, and antibodies are designated according to the nomenclature recommended by the ISBT working party on terminology for red cell surface antigens.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
Gb4Cer, globotetraosylceramide/globoside/GalNAc
3Gal
4Gal
4GlcCer;
Gb3Cer, globotriaosylceramide, Gal
4Gal
4GlcCer;
4Gal-T, 4-
-galactosyltransferase,
Gb3Cer/Pk/CD77 synthase;
3GalNAc-T1, 3-
-N-acetylgalactosaminyltransferase,
Gb4Cer/globoside synthase;
3Gal-T1 to T5, 3-
-galactosyltransferase 1 to 5;
ISBT, International Society of
Blood Transfusion;
PCR-SSP, polymerase chain reaction with
sequence-specific primers;
nt, nucleotide.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Matson, G. A., Swanson, J., Noades, J., Sanger, R., and Race, R. R. (1959) Am. J. Hum. Genet. 11, 26-34[Medline] [Order article via Infotrieve] |
| 2. | Naiki, M., and Marcus, D. M. (1974) Biochem. Biophys. Res. Commun. 60, 1105-1111[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Cooling, L. L., Koerner, T. A., and Naides, S. J. (1995) J. Infect. Dis. 172, 1198-1205[Medline] [Order article via Infotrieve] |
| 4. | Naiki, M., and Marcus, D. M. (1975) Biochemistry 14, 4837-4841[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Kijimoto-Ochiai, S.,
Naiki, M.,
and Makita, A.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5407-5410 |
| 6. | Daniels, G. L., Anstee, D. J., Cartron, J. P., Dahr, W., Issitt, P. D., Jorgensen, J., Kornstad, L., Levene, C., Lomas-Francis, C., Lubenko, A., et al.. (1995) Vox Sang. 69, 265-279[Medline] [Order article via Infotrieve] |
| 7. | Marcus, D. M. (1989) Immunol. Ser. 43, 701-712[Medline] [Order article via Infotrieve] |
| 8. |
Steffensen, R.,
Carlier, K.,
Wiels, J.,
Levery, S. B.,
Stroud, M.,
Cedergren, B.,
Nilsson, S. B.,
Bennett, E. P.,
Jersild, C.,
and Clausen, H.
(2000)
J. Biol. Chem.
275,
16723-16729 |
| 9. |
Kojima, Y.,
Fukumoto, S.,
Furukawa, K.,
Okajima, T.,
Wiels, J.,
Yokoyama, K.,
Suzuki, Y.,
Urano, T.,
Ohta, M.,
and Furukawa, K.
(2000)
J. Biol. Chem.
275,
15152-15156 |
| 10. |
Keusch, J. J.,
Manzella, S. M.,
Nyame, K. A.,
Cummings, R. D.,
and Baenziger, J. U.
(2000)
J. Biol. Chem.
275,
25315-25321 |
| 11. |
Furukawa, K.,
Iwamura, K.,
Uchikawa, M.,
Sojka, B. N.,
Wiels, J.,
Okajima, T.,
Urano, T.,
and Furukawa, K.
(2000)
J. Biol. Chem.
275,
37752-37756 |
| 12. |
Okajima, T.,
Nakamura, Y.,
Uchikawa, M.,
Haslam, D. B.,
Numata, S. I.,
Furukawa, K.,
Urano, T.,
and Furukawa, K.
(2000)
J. Biol. Chem.
275,
40498-40503 |
| 13. |
Amado, M.,
Almeida, R.,
Carneiro, F.,
Levery, S. B.,
Holmes, E. H.,
Nomoto, M.,
Hollingsworth, M. A.,
Hassan, H.,
Schwientek, T.,
Nielsen, P. A.,
Bennett, E. P.,
and Clausen, H.
(1998)
J. Biol. Chem.
273,
12770-12778 |
| 14. | Race, R. R., and Sanger, R. (1975) The P Blood Groups, Blood Groups in Man , pp. 139-177, Blackwell Scientific Publications, Oxford, UK |
| 15. | Cedergren, B. (1973) Hereditas 73, 27-30[Medline] [Order article via Infotrieve] |
| 16. | Daniels, G. (1995) P Blood Groups, Human Blood Groups , pp. 227-256, Blackwell Scientific, Oxford, UK |
| 17. | Spitalnik, P. F., and Spitalnik, S. L. (1995) Transfus. Med. Rev. 9, 110-122[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Cantin, G., and Lyonnais, J. (1983) Transfusion 23, 350-351[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Lindstrom, K., Dem Borne, A. E., Breimer, M. E., Cedergren, B., Okubo, Y., Rydberg, L., Teneberg, S., and Samuelsson, B. E. (1992) Glycoconj. J. 9, 325-329[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Heddle, N. M. (1989) Transfus. Med. Rev. 3, 219-229[Medline] [Order article via Infotrieve] |
| 21. |
Brown, K. E.,
Anderson, S. M.,
and Young, N. S.
(1993)
Science
262,
114-117 |
| 22. | Brown, K. E., and Young, N. S. (1995) Blood Rev. 9, 176-182[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Brown, K. E.,
Hibbs, J. R.,
Gallinella, G.,
Anderson, S. M.,
Lehman, E. D.,
McCarthy, P.,
and Young, N. S.
(1994)
N. Engl. J. Med.
330,
1192-1196 |
| 24. | Lindberg, F. P., Lund, B., and Normark, S. (1984) EMBO J. 3, 1167-1173[Medline] [Order article via Infotrieve] |
| 25. |
Miller, S. A.,
Dykes, D. D.,
and Polesky, H. F.
(1988)
Nucleic Acids Res.
16,
1215 |
| 26. |
Olsson, M. L.,
Irshaid, N. M.,
Hosseini-Maaf, B.,
Hellberg, Å.,
Moulds, M. K.,
Sareneva, H.,
and Chester, M. A.
(2001)
Blood
98,
1585-1593 |
| 27. | Irshaid, N. M., Henry, S. M., and Olsson, M. L. (2000) Transfusion 40, 69-74[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Yamamoto, F., Clausen, H., White, T., Marken, J., and Hakomori, S. (1990) Nature 345, 229-233[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Koda, Y., Soejima, M., Liu, Y., and Kimura, H. (1996) Am. J. Hum. Genet. 59, 343-350[Medline] [Order article via Infotrieve] |
| 30. |
Paulson, J. C.,
and Colley, K. J.
(1989)
J. Biol. Chem.
264,
17615-17618 |
| 31. | Yamamoto, F., McNeill, P. D., Yamamoto, M., Hakomori, S., Bromilow, I. M., and Duguid, J. K. (1993) Vox Sang. 64, 175-178[Medline] [Order article via Infotrieve] |
| 32. |
Yamamoto, F.,
and McNeill, P. D.
(1996)
J. Biol. Chem.
271,
10515-10520 |
| 33. | Gastinel, L. N., Bignon, C., Misra, A. K., Hindsgaul, O., Shaper, J. H., and Joziasse, D. H. (2001) EMBO J. 20, 638-649[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Isshiki, S.,
Togayachi, A.,
Kudo, T.,
Nishihara, S.,
Watanabe, M.,
Kubota, T.,
Kitajima, M.,
Shiraishi, N.,
Sasaki, K.,
Andoh, T.,
and Narimatsu, H.
(1999)
J. Biol. Chem.
274,
12499-12507 |
| 35. |
Zhou, D.,
Dinter, A.,
Gutierrez, G. R.,
Kamerling, J. P.,
Vliegenthart, J. F.,
Berger, E. G.,
and Hennet, T.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
406-411 |
| 36. | Yuan, Y. P., Schultz, J., Mlodzik, M., and Bork, P. (1997) Cell 88, 9-11[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
H. H. Wandall, J. W. Pedersen, C. Park, S. B. Levery, S. Pizette, S. M. Cohen, T. Schwientek, and H. Clausen Drosophila egghead Encodes a beta 1,4-Mannosyltransferase Predicted to Form the Immediate Precursor Glycosphingolipid Substrate for brainiac J. Biol. Chem., January 10, 2003; 278(3): 1411 - 1414. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Schwientek, B. Keck, S. B. Levery, M. A. Jensen, J. W. Pedersen, H. H. Wandall, M. Stroud, S. M. Cohen, M. Amado, and H. Clausen The Drosophila Gene brainiac Encodes a Glycosyltransferase Putatively Involved in Glycosphingolipid Synthesis J. Biol. Chem., August 30, 2002; 277(36): 32421 - 32429. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |